Cargando…
Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin
BACKGROUND: COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease. METHODS: This prospective, observati...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592075/ https://www.ncbi.nlm.nih.gov/pubmed/34782921 http://dx.doi.org/10.1007/s00392-021-01970-4 |
_version_ | 1784599387172765696 |
---|---|
author | Kaufmann, Christoph C. Ahmed, Amro Kassem, Mona Freynhofer, Matthias K. Jäger, Bernhard Aicher, Gabriele Equiluz-Bruck, Susanne Spiel, Alexander O. Vafai-Tabrizi, Florian Gschwantler, Michael Fasching, Peter Wojta, Johann Giannitsis, Evangelos Huber, Kurt |
author_facet | Kaufmann, Christoph C. Ahmed, Amro Kassem, Mona Freynhofer, Matthias K. Jäger, Bernhard Aicher, Gabriele Equiluz-Bruck, Susanne Spiel, Alexander O. Vafai-Tabrizi, Florian Gschwantler, Michael Fasching, Peter Wojta, Johann Giannitsis, Evangelos Huber, Kurt |
author_sort | Kaufmann, Christoph C. |
collection | PubMed |
description | BACKGROUND: COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease. METHODS: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from June 6th to November 26th, 2020 in a tertiary care hospital. Copeptin and high-sensitive cardiac troponin I (hs-cTnI) levels on admission were collected and tested for their association with the primary composite endpoint of ICU admission or 28-day mortality. RESULTS: A total of 213 eligible patients with COVID-19 were included of whom 55 (25.8%) reached the primary endpoint. Median levels of copeptin and hs-cTnI at admission were significantly higher in patients with an adverse outcome (Copeptin 29.6 pmol/L, [IQR, 16.2–77.8] vs 17.2 pmol/L [IQR, 7.4–41.0] and hs-cTnI 22.8 ng/L [IQR, 11.5–97.5] vs 10.2 ng/L [5.5–23.1], P < 0.001 respectively). ROC analysis demonstrated an optimal cut-off of 19.3 pmol/L for copeptin and 16.8 ng/L for hs-cTnI and an increase of either biomarker was significantly associated with the primary endpoint. The combination of raised hs-cTnI and copeptin yielded a superior prognostic value to individual measurement of biomarkers and was a strong prognostic marker upon multivariable logistic regression analysis (OR 4.274 [95% CI, 1.995–9.154], P < 0.001). Addition of copeptin and hs-cTnI to established risk models improved C-statistics and net reclassification indices. CONCLUSION: The combination of raised copeptin and hs-cTnI upon admission is an independent predictor of ICU admission or 28-day mortality in hospitalized patients with COVID-19. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01970-4. |
format | Online Article Text |
id | pubmed-8592075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85920752021-11-15 Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin Kaufmann, Christoph C. Ahmed, Amro Kassem, Mona Freynhofer, Matthias K. Jäger, Bernhard Aicher, Gabriele Equiluz-Bruck, Susanne Spiel, Alexander O. Vafai-Tabrizi, Florian Gschwantler, Michael Fasching, Peter Wojta, Johann Giannitsis, Evangelos Huber, Kurt Clin Res Cardiol Original Paper BACKGROUND: COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease. METHODS: This prospective, observational study of patients with laboratory-confirmed COVID-19 infection was conducted from June 6th to November 26th, 2020 in a tertiary care hospital. Copeptin and high-sensitive cardiac troponin I (hs-cTnI) levels on admission were collected and tested for their association with the primary composite endpoint of ICU admission or 28-day mortality. RESULTS: A total of 213 eligible patients with COVID-19 were included of whom 55 (25.8%) reached the primary endpoint. Median levels of copeptin and hs-cTnI at admission were significantly higher in patients with an adverse outcome (Copeptin 29.6 pmol/L, [IQR, 16.2–77.8] vs 17.2 pmol/L [IQR, 7.4–41.0] and hs-cTnI 22.8 ng/L [IQR, 11.5–97.5] vs 10.2 ng/L [5.5–23.1], P < 0.001 respectively). ROC analysis demonstrated an optimal cut-off of 19.3 pmol/L for copeptin and 16.8 ng/L for hs-cTnI and an increase of either biomarker was significantly associated with the primary endpoint. The combination of raised hs-cTnI and copeptin yielded a superior prognostic value to individual measurement of biomarkers and was a strong prognostic marker upon multivariable logistic regression analysis (OR 4.274 [95% CI, 1.995–9.154], P < 0.001). Addition of copeptin and hs-cTnI to established risk models improved C-statistics and net reclassification indices. CONCLUSION: The combination of raised copeptin and hs-cTnI upon admission is an independent predictor of ICU admission or 28-day mortality in hospitalized patients with COVID-19. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00392-021-01970-4. Springer Berlin Heidelberg 2021-11-15 2022 /pmc/articles/PMC8592075/ /pubmed/34782921 http://dx.doi.org/10.1007/s00392-021-01970-4 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Kaufmann, Christoph C. Ahmed, Amro Kassem, Mona Freynhofer, Matthias K. Jäger, Bernhard Aicher, Gabriele Equiluz-Bruck, Susanne Spiel, Alexander O. Vafai-Tabrizi, Florian Gschwantler, Michael Fasching, Peter Wojta, Johann Giannitsis, Evangelos Huber, Kurt Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin |
title | Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin |
title_full | Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin |
title_fullStr | Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin |
title_full_unstemmed | Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin |
title_short | Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin |
title_sort | improvement of outcome prediction of hospitalized patients with covid-19 by a dual marker strategy using high-sensitive cardiac troponin i and copeptin |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592075/ https://www.ncbi.nlm.nih.gov/pubmed/34782921 http://dx.doi.org/10.1007/s00392-021-01970-4 |
work_keys_str_mv | AT kaufmannchristophc improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT ahmedamro improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT kassemmona improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT freynhofermatthiask improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT jagerbernhard improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT aichergabriele improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT equiluzbrucksusanne improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT spielalexandero improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT vafaitabriziflorian improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT gschwantlermichael improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT faschingpeter improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT wojtajohann improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT giannitsisevangelos improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin AT huberkurt improvementofoutcomepredictionofhospitalizedpatientswithcovid19byadualmarkerstrategyusinghighsensitivecardiactroponiniandcopeptin |